LivaNovaLIVN
LIVN
About: UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Employees: 2,900
0
Funds holding %
of 7,202 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
14% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 85
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
1.97% less ownership
Funds ownership: 100.25% [Q4 2024] → 98.28% (-1.97%) [Q1 2025]
5% less funds holding
Funds holding: 255 [Q4 2024] → 242 (-13) [Q1 2025]
17% less capital invested
Capital invested by funds: $2.52B [Q4 2024] → $2.1B (-$425M) [Q1 2025]
19% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 43
86% less call options, than puts
Call options by funds: $199K | Put options by funds: $1.46M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
23%
upside
Avg. target
$59
32%
upside
High target
$64
43%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
Wolfe Research Mike Polark | 34%upside $60 | Outperform Upgraded | 20 May 2025 |
Needham Mike Matson | 43%upside $64 | Buy Reiterated | 13 May 2025 |
Barclays Matt Miksic | 23%upside $55 | Equal-Weight Maintained | 8 May 2025 |
Baird David Rescott | 36%upside $61 | Outperform Maintained | 8 May 2025 |
Goldman Sachs David Roman | 23%upside $55 | Buy Maintained | 3 Mar 2025 |
Financial journalist opinion
Based on 5 articles about LIVN published over the past 30 days
Neutral
Business Wire
5 days ago
LivaNova to Present at the Jefferies Global Healthcare Conference
LONDON--(BUSINESS WIRE)-- #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on.
Neutral
Seeking Alpha
1 week ago
LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Briana Gotlin – Vice President, Investor Relations Vladimir Makatsaria – Chief Executive Officer Ahmet Tezel – Chief Innovation Officer Alex Shvartsburg – Chief Financial Officer Stephanie Bolton – President, Global Epilepsy Conference Call Participants Rick Wise – Stifel David Roman – Goldman Sachs Adam Maeder – Piper Sandler Mike Sarcone – Jefferies Mike Matson – Needham & Co. David Rescott – Baird Michael Polark – Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC First Quarter 2025 Earnings Conference Call. My name is Emily, and I'll be coordinating your call today.
Positive
Zacks Investment Research
1 week ago
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago.
Neutral
Business Wire
1 week ago
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights(1) First-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organic basis as compared to the prior-year period First-quarter U.S. GAAP diluted loss per share of $6.01, impacted by recording SNIA.
Neutral
Business Wire
1 week ago
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and an A.
Neutral
Business Wire
1 month ago
LivaNova to Announce First-Quarter 2025 Results
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2025 results on Wed., May 7, 2025, at 1 p.m. London time (8 a.m. Eastern Time).
Neutral
Seeking Alpha
2 months ago
LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript
LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
2 months ago
LivaNova (LIVN) Tops Q4 Earnings Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.87 per share a year ago.
Neutral
Business Wire
2 months ago
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance.
Neutral
Business Wire
2 months ago
LivaNova to Present at the Barclays Global Healthcare Conference
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should.
Charts implemented using Lightweight Charts™